Prof. Hui Wang 王徽
Chief Physician, Professor
Interventional Therapy Center, Jilin Cancer Hospital, Changchun
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Interventional treatment for lung cancer, brain metastases, liver cirrhosis with hypersplenism, adrenal cancer, metastatic cancer, high bile duct cancer with obstructive jaundice, and esophageal cancer.
Dr. Wang holds a medical doctorate from Jilin University (1999) and studied in Japan (1995) and Italy (2010). With 27 years in minimally invasive interventional oncology, Dr. Wang serves as Director of the Interventional Department at Jilin Cancer Hospital. Research focuses on vascular intervention, 125I radioactive seed implantation, and microwave ablation for liver and lung cancers. Dr. Wang has published over 30 academic papers.
Professional roles
- Standing Committee Member, Minimally Invasive Tumor Treatment Professional Committee, China Anti-Cancer Association
- Vice Chair, Lung Cancer Minimally Invasive Comprehensive Treatment Branch, China Anti-Cancer Association
- Vice Chair, Tumor Emergency Minimally Invasive Treatment Branch, China Anti-Cancer Association
- Chair, Interventional Oncology Professional Committee, Jilin Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Hui). Papers usually list the name as Hui Wang or Wang H.
Selected publications
14 papers on PubMed matched by name and affiliation; 2 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Res Hepatol Gastroenterol, 2022 (first author): Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study. PubMed 35108656
- Oncol Lett, 2018 (senior author): Oridonin increases anticancer effects of lentinan in HepG2 human hepatoblastoma cells. PubMed 29434900
- Cancer, 2015 (first author): Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma. PubMed 26033499
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion